비교리스트

 카트 문의
시장보고서
상품코드
1698006

세계의 환각제 시장 : 산업 규모, 점유율, 동향, 기회＆예측, 약물 유형별, 용도별, 유통 채널별, 지역별, 경쟁별(2020-2030년)

Psychedelic Drug Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Drug Type, By Application, By Distribution Channel, By Region & Competition, 2020-2030F
발행일: | 리서치사: TechSci Research | 페이지 정보: 영문 186 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

환각제 세계 시장 규모는 2024년 45억 5,000만 달러에 달했고, 2030년까지 예측 기간 동안 연평균 10.55%의 괄목할만한 성장이 예상됩니다.

세계 환각제 시장은 임상연구의 눈부신 발전, 규제 프레임워크의 진화, 사회적 인식의 변화 등에 힘입어 새로운 관심 증가와 확대가 이루어지고 있습니다. 특히 우울증, 불안장애, 외상 후 스트레스 장애(PTSD)와 같은 정신질환의 유병률이 증가함에 따라 혁신적이고 효과적인 치료 솔루션에 대한 수요가 급증하고 있습니다. 환각제 기반 치료제는 기존 항우울제에 대한 파괴적인 대안으로 각광받고 있으며, 임상시험에서 빠른 효과 발현과 지속적인 효능을 입증하고 있습니다.

시장 개요
예측 기간 2026-2030년
시장 규모 : 2024년 45억 5,000만 달러
시장 규모 : 2030년 83억 2,000만 달러
CAGR : 2025-2030년 10.55%
급성장 부문 병원 약국
최대 시장 북미

시장 성장은 정신 건강에 대한 인식 증가, 진보적인 정책 개혁, 환각제의 의학적 유용성을 뒷받침하는 과학적 증거 증가로 인해 더욱 가속화되고 있습니다. 제약회사, 생명공학 기업 및 연구기관 간의 전략적 파트너십은 의약품 개발 파이프라인을 가속화하고 정신의학 분야에서 환각제 화합물이 주류에 통합될 수 있는 가능성을 높이고 있습니다. 규제 당국의 승인이 확대되고 연구개발에 대한 투자가 강화됨에 따라 환각제 시장은 장기적으로 크게 성장할 준비가 되어 있습니다.

주요 시장 성장 촉진요인

정신질환 유병률 증가

주요 시장 이슈

규제상의 장애물

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 세계의 환각제 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 약물 유형별(Lysergic Acid Diethylamide, Gamma, Hydroxybutyric Acid, Ketamine, Psilocybin, 기타)
    • 용도별(치료 저항성 우울증, 마약 중독, 외상 후 스트레스 장애, 기면증, 패닉 장애, 기타)
    • 유통 채널별(병원 약국, 소매 약국, 온라인 약국)
    • 지역별
    • 기업별(2024년)
  • 제품 시장 맵
    • 약 유형별
    • 용도별
    • 유통 채널별
    • 지역별

제6장 북미의 환각제 시장 전망

  • 시장 규모와 예측
  • 시장 점유율과 예측
  • 북미 : 국가별 분석
    • 미국
    • 캐나다
    • 멕시코

제7장 유럽의 환각제 시장 전망

  • 시장 규모와 예측
  • 시장 점유율과 예측
  • 유럽 : 국가별 분석
    • 독일
    • 영국
    • 프랑스
    • 이탈리아
    • 스페인

제8장 아시아태평양의 환각제 시장 전망

  • 시장 규모와 예측
  • 시장 점유율과 예측
  • 아시아태평양 : 국가별 분석
    • 중국
    • 일본
    • 인도
    • 호주
    • 한국

제9장 남미의 환각제 시장 전망

  • 시장 규모와 예측
  • 시장 점유율과 예측
  • 남미 : 국가별 분석
    • 브라질
    • 아르헨티나
    • 콜롬비아

제10장 중동 및 아프리카의 환각제 시장 전망

  • 시장 규모와 예측
  • 시장 점유율과 예측
  • 중동 및 아프리카 : 국가별 분석
    • 남아프리카공화국
    • 사우디아라비아
    • 아랍에미리트

제11장 시장 역학

  • 성장 촉진요인
  • 과제

제12장 시장 동향과 발전

  • 최근 동향
  • 인수합병(M&A)
  • 제품 출시

제13장 Porter의 Five Forces 분석

  • 업계내 경쟁
  • 신규 참여 가능성
  • 공급업체의 힘
  • 고객의 힘
  • 대체품의 위협

제14장 경쟁 구도

  • Jazz Pharmaceuticals PLC
  • NeonMind Biosciences Inc.
  • Cybin Inc.
  • Pfizer Inc
  • Numinus Wellness Inc
  • Mind Medicine Inc
  • PharmaTher Holdings Ltd
  • NRX Pharmaceuticals Inc
  • Seelos Therapeutics Inc
  • Revive Therapeutics Inc

제15장 전략적 제안

제16장 리서치사에 대해 & 면책사항

LSH 25.04.22

Global Psychedelic Drug Market was valued at USD 4.55 Billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 10.55% through 2030. The global psychedelic drug market is witnessing a renewed surge in interest and expansion, fueled by significant advancements in clinical research, evolving regulatory frameworks, and shifting societal perceptions. The rising prevalence of mental health disorders-particularly depression, anxiety, and post-traumatic stress disorder (PTSD)-has created an urgent demand for innovative and effective treatment solutions. Psychedelic-based therapeutics are gaining traction as a disruptive alternative to conventional antidepressants, demonstrating both rapid onset and sustained efficacy in clinical trials.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 4.55 Billion
Market Size 2030USD 8.32 Billion
CAGR 2025-203010.55%
Fastest Growing SegmentHospital Pharmacies
Largest MarketNorth America

Market growth is being further catalyzed by increasing mental health awareness, progressive policy reforms, and a growing body of scientific evidence supporting the medical utility of psychedelics. Strategic partnerships between pharmaceutical companies, biotech firms, and research institutions are accelerating drug development pipelines, positioning psychedelic compounds for potential mainstream integration within psychiatric care. As regulatory approvals expand and investment in research and development intensifies, the psychedelic drug market is poised for substantial long-term growth.

Key Market Drivers

Rising Prevalence of Mental Health Disorders

The increasing global prevalence of mental health disorders is one of the most significant catalysts driving the growth of the psychedelic drugs market. As traditional treatment approaches struggle to meet the rising demand for effective solutions, psychedelic-assisted therapies are emerging as a disruptive innovation in psychiatric care. The burden of mental health disorders has reached unprecedented levels, with conditions such as depression, anxiety, and post-traumatic stress disorder (PTSD) affecting millions worldwide. According to data from the World Health Organization (WHO), depression affects more than 284 million individuals worldwide, making it one of the most widespread mental health conditions. Similarly, over 264 million people are impacted by anxiety disorders, highlighting the growing demand for effective mental health interventions. Despite these alarming statistics, conventional treatments-including selective serotonin reuptake inhibitors (SSRIs) and cognitive-behavioral therapy (CBT)-often produce suboptimal results, with many patients experiencing delayed symptom relief, treatment resistance, or severe side effects. This growing treatment gap has created a strong demand for innovative therapies, positioning psychedelics as a viable alternative.

Key Market Challenges

Regulatory Hurdles

Perhaps the most significant challenge facing the psychedelic drug market is the complex and evolving regulatory landscape. Many psychedelics are classified as controlled substances due to their historical association with recreational use and concerns about safety and abuse potential. Navigating these regulations can be a lengthy and expensive process, often requiring years of clinical trials and regulatory approvals.

Key Market Players

  • Jazz Pharmaceuticals PLC
  • NeonMind Biosciences Inc.
  • Cybin Inc.
  • Pfizer Inc
  • Numinus Wellness Inc
  • Mind Medicine Inc
  • PharmaTher Holdings Ltd
  • NRX Pharmaceuticals Inc
  • Seelos Therapeutics Inc
  • Revive Therapeutics Inc

Report Scope:

In this report, the Global Psychedelic Drug Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Psychedelic Drug Market, By Drug Type:

  • Lysergic Acid Diethylamide
  • Gamma Hydroxybutyric Acid
  • Ketamine
  • Psilocybin
  • Others

Psychedelic Drug Market, By Application:

  • Treatment-Resistant Depression
  • Opiate Addiction
  • Post-Traumatic Stress Disorder
  • Narcolepsy
  • Panic Disorders
  • Others

Psychedelic Drug Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Psychedelic Drug Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Psychedelic Drug Market.

Available Customizations:

Global Psychedelic Drug market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Psychedelic Drug Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Type (Lysergic Acid Diethylamide, Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Others)
    • 5.2.2. By Application (Treatment-Resistant Depression, Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Others)
    • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 5.2.4. By Region
    • 5.2.5. By Company (2024)
  • 5.3. Product Market Map
    • 5.3.1. By Drug Type
    • 5.3.2. By Application
    • 5.3.3. By Distribution Channel
    • 5.3.4. By Region

6. North America Psychedelic Drug Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Type (Lysergic Acid Diethylamide, Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Others)
    • 6.2.2. By Application (Treatment-Resistant Depression, Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Others)
    • 6.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Psychedelic Drug Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Type
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Canada Psychedelic Drug Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Type
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Mexico Psychedelic Drug Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Type
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By Distribution Channel

7. Europe Psychedelic Drug Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Type (Lysergic Acid Diethylamide, Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Others)
    • 7.2.2. By Application (Treatment-Resistant Depression, Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Others)
    • 7.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Psychedelic Drug Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Type
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. United Kingdom Psychedelic Drug Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Type
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. France Psychedelic Drug Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Type
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. Italy Psychedelic Drug Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Type
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. Spain Psychedelic Drug Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Type
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Psychedelic Drug Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Type (Lysergic Acid Diethylamide, Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Others)
    • 8.2.2. By Application (Treatment-Resistant Depression, Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Others)
    • 8.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Psychedelic Drug Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Type
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. Japan Psychedelic Drug Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Type
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. India Psychedelic Drug Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Type
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. Australia Psychedelic Drug Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Type
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. South Korea Psychedelic Drug Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Type
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By Distribution Channel

9. South America Psychedelic Drug Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Type (Lysergic Acid Diethylamide, Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Others)
    • 9.2.2. By Application (Treatment-Resistant Depression, Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Others)
    • 9.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Psychedelic Drug Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Type
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. Argentina Psychedelic Drug Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Type
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. Colombia Psychedelic Drug Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Type
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Psychedelic Drug Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Type (Lysergic Acid Diethylamide, Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Others)
    • 10.2.2. By Application (Treatment-Resistant Depression, Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Others)
    • 10.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Psychedelic Drug Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Type
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Saudi Arabia Psychedelic Drug Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Type
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. UAE Psychedelic Drug Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Type
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. Jazz Pharmaceuticals PLC
    • 14.1.1. Business Overview
    • 14.1.2. Product & Service Offerings
    • 14.1.3. Recent Developments
    • 14.1.4. Financials (If Listed)
    • 14.1.5. Key Personnel
    • 14.1.6. SWOT Analysis
  • 14.2. NeonMind Biosciences Inc.
  • 14.3. Cybin Inc.
  • 14.4. Pfizer Inc
  • 14.5. Numinus Wellness Inc
  • 14.6. Mind Medicine Inc
  • 14.7. PharmaTher Holdings Ltd
  • 14.8. NRX Pharmaceuticals Inc
  • 14.9. Seelos Therapeutics Inc
  • 14.10. Revive Therapeutics Inc

15. Strategic Recommendations

16. About Us & Disclaimer

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제